Medios AG / Key word(s): Change in Forecast/Half Year Results
Ad hoc Release
Medios AG raises its forecast for fiscal year 2017 due to the positive development in the first half-year
This means that Medios has already reached more than half of the amounts expected for the whole year. As a result, the Management Board raises the forecast for sales revenue from around EUR 200 million to EUR 230 million. The forecast for EBT* is raised from around EUR 7 million to a target range from EUR 7,0 to 7,5 million, which takes into account impacts from growth investments and non-predictable consequences of the prohibition of public tendering on cytostatic drugs through the German Act on Strengthening Pharmaceutical Supply in Statutory Health Insurance.
The full half-year financial report of Medios AG will be published in September 2017 at http://medios.ag/en/investor-relations/financial-reports/.
* EBT is defined as net earnings before income taxes
About Medios AG
With our subsidiaries Medios Pharma, Medios Manufaktur and Medios Digital we connect individual market players to form cooperating partners. Our goal is to provide partners and customers with integrated solutions along the value chain, ensuring optimal patient care.
Medios AG is Germany's first listed Specialty Pharma company. The share (WKN: A1MMCC, ISIN: DE000A1MMCC8) is listed in the Regulated Market of the Frankfurt Stock Exchange (General Standard).
|Phone:||+49 30 232 566 - 800|
|Fax:||030 / 8321 8377|
|Listed:||Regulated Market in Frankfurt (General Standard), Hamburg; Regulated Unofficial Market in Dusseldorf|
|End of Announcement||DGAP News Service|